Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.9600 (4.01%) ($5.7400 - $6.4100) on Thu. May. 16, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.81% (three month average) | RSI | 35 | Latest Price | $5.9600(4.01%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ADMS declines -5.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XOP(12%) OIH(11%) EWI(9%) XRT(9%) IGOV(8%) | Factors Impacting ADMS price | ADMS will decline at least -2.405% in a week (0% probabilities). BNDX(-10%) GLD(-9%) GDX(-9%) GDXJ(-8%) BWX(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.405% (StdDev 4.81%) | Hourly BBV | 0 () | Intraday Trend | 3.8% | | | |
|
1 - 5 Day Possible Target | $-3.84(-164.43%) | Resistance Level | $6.1 | 5 Day Moving Average | $5.65(5.49%) | 10 Day Moving Average | $5.88(1.36%) | 20 Day Moving Average | $6.1(-2.3%) | To recent high | -50.9% | To recent low | 8.8% | Market Cap | $169m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |